What is the response rate for intrathecal chemotherapy in lung cancer leptomeningeal metastasis?
Leptomeningeal metastasis (LM) means cancer has spread to the thin layers of tissue and fluid around the brain and spinal cord. In lung cancer, it is a serious complication. Intrathecal chemotherapy means giving drugs directly into the fluid around the spinal cord, either by lumbar puncture (a needle in the lower back) or through an Ommaya reservoir (a small device placed under the scalp) 25. The short answer: response rates vary widely. A systematic review of 12 studies found objective response rates of 34.5% to 86.4% 28. Some single-drug trials report rates near 80% 7. The range is wide because studies use different drugs, different delivery methods, and different ways of measuring response.
What the research says
The broadest number comes from a systematic review of 12 clinical studies covering 544 patients with non-small-cell lung cancer (NSCLC) and LM. Objective response rates ranged from 34.5% to 86.4%, and disease control rates (response plus stable disease) ranged from 62.5% to 94.9% 28. Drugs were given by lumbar puncture or Ommaya reservoir. Median overall survival across trials ranged from 3.66 to 17 months 28. That wide spread shows how much results depend on the specific treatment and the patients studied.
What to ask your doctor
- Given my specific lung cancer type and prior treatments, what response rate might I expect from intrathecal chemotherapy?
- Which drug would you use intrathecally, and how does the evidence for it compare with other options?
- Would an Ommaya reservoir or lumbar puncture be better for me, and what are the tradeoffs?
- How will you measure whether the treatment is working (for example, symptoms, imaging, or cerebrospinal fluid tests)?
- What side effects should I watch for, and how are they usually managed?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.